The National Pharmaceutical Pricing Authority announced measures to cap trade margins on 137 anti-cancer drugs, with reported price reductions of up to 70% for affected medicines. Trade-margin regulation aims to limit the difference between the price at which a product is supplied and the price charged further along the distribution chain. Cancer treatment can impose a substantial financial burden on patients and families. Measures to improve affordability may help patients access essential medicines, but implementation requires transparent pricing, monitoring of availability and compliance by manufacturers and sellers. Affordability policy must also ensure that price controls do not create avoidable supply shortages. The actual benefit should be assessed through medicine prices and patient access after implementation.